Cancer Family
Stromal Neoplasm
CI-CAN-00000360Explore in graph →
Non-malignant52 active trials2 approved drugs89 evidence items
- NCIt
- C6781
Loading cancer entity…
Cancer Family
CI-CAN-00000360Explore in graph →
Clinical trials
355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03602092 | Observational Registry Data on GIST Patients | completed | — | 966 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07454967 | Development of a Multimodal AI System for GIST Management | completed | — | 300 | Qun ZhaoOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03556384 |
| Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) |
| completed |
| Phase 2 |
| 23 |
| Adam Burgoyne, MD, PhDOTHER |
| 1 |
| Jul 28, 2026 |
| clinicaltrials |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | completed | Phase 4 | 34 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 16, 2026 | clinicaltrials |
| NCT07614841 | To Explore the Optimal Therapeutic Window for Imatinib in the Adjuvant Treatment of Intermediate and High-risk Gastrointestinal Stromal Tumors | completed | — | 328 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | May 29, 2026 | clinicaltrials |
| NCT03944304 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | completed | Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04633122 | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib | completed | Phase 2 | 108 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05381753 | Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World | completed | — | 61 | CStone PharmaceuticalsINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06619275 | Ripretinib (QINLOCK®) According to Current SmPC(INTEREST) | completed | — | 10 | iOMEDICO AGINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04258956 | A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy(AXAGIST) | completed | Phase 2 | 58 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT01907607 | Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(CYCLIGIST) | completed | Phase 2 | 29 | Institut BergoniéOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT04811196 | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | completed | Phase 1 | 56 | University Health Network, TorontoOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT04282980 | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | completed | Phase 2 | 39 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06038552 | Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM | completed | — | 238 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02401815 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 51 | Cogent Biosciences, Inc.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT00780494 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04908176 | A Drug-drug Interaction Study of Avapritinib and Midazolam | completed | Phase 1 | 10 | Blueprint Medicines CorporationINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT04825574 | Study for Patients Previously Treated in Avapritinib Clinical Trials | completed | Phase 4 | 2 | Blueprint Medicines CorporationINDUSTRY | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06628739 | Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes | completed | — | 168 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04530981 | A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST | completed | Phase 1 | 13 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01863745 | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | completed | Phase 2 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 19, 2024 | clinicaltrials |
| NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | completed | Phase 2 | 26 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
| NCT01738139 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | completed | Phase 1 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT04599660 | Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)(RetroGIST) | completed | — | 700 | Italian Sarcoma GroupNETWORK | 1 | Feb 1, 2024 | clinicaltrials |
| NCT02260505 | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)(ImadGist) | completed | Phase 3 | 136 | Centre Leon BerardOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | completed | Phase 1 | 282 | Deciphera Pharmaceuticals, LLCINDUSTRY | 6 | Dec 13, 2023 | clinicaltrials |
| NCT04006769 | Entacapone Combination With Imatinib for Treatment of GIST | completed | Early Phase 1 | 5 | Xiangya Hospital of Central South UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 164 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT01376505 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | completed | Phase 1 | 65 | Robert WesolowskiOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT00764595 | Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor(GISTs) | completed | Phase 2 | 5 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT00769782 | Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor(GISTs) | completed | Phase 2 | 6 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT04254939 | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor | completed | Phase 1 / Phase 2 | 65 | CStone PharmaceuticalsINDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT00716820 | Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). | completed | — | 472 | PfizerINDUSTRY | 0 | Apr 6, 2023 | clinicaltrials |
| NCT05796700 | Microwave Ablation Versus Laparoscopic Hepatectomy for 3-5cm Hepatocellular Carcinoma | completed | N/A | 1,585 | Chinese PLA General HospitalOTHER | 0 | Apr 3, 2023 | clinicaltrials |
| NCT02638766 | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST(REGISTRI) | completed | Phase 2 | 15 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT04476082 | Nutrition in Gastrointestinal Tumors(NutriGIT) | completed | — | 66 | University Medicine GreifswaldOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02712112 | A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs | completed | Phase 2 | 51 | Asan Medical CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03609424 | PDR001 Plus Imatinib for Metastatic or Unresectable GIST | completed | Phase 1 / Phase 2 | 39 | Asan Medical CenterOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05565066 | A Real-world Comparison of FNB and FNA in IHC-required Lesions. | completed | — | 439 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03353753 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies(INVICTUS) | completed | Phase 3 | 129 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Nov 21, 2022 | clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03465722 | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | completed | Phase 3 | 476 | Blueprint Medicines CorporationINDUSTRY | 18 | Oct 6, 2022 | clinicaltrials |
| NCT02880020 | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials